RTRui Tao

Rui Tao

*This is an algorithmically generated author record based on publicly available information.

Rui Tao has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Thermosensitive Hydrogel Combined with Pirarubicin via TACE for Hepatocellular Carcinoma: A Pilot Study

    by Chang Liu, Qihui Hu, Baoyong Zhou, Xiang Zhang, Rui Tao

    Aim: This pilot study aims to evaluate the technical feasibility, safety profile, and preliminary efficacy of Tepoxin, a thermosensitive hydrogel, combined with pirarubicin via transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC), providing foundational data for future larger-scale trials. Methods: This is a single-center, retrospective, single-arm pilot study including 7 HCC patients who received Tepoxin combined with pirarubicin TACE between 2023 and 2025. Inclusion criteria were: confirmed HCC by imaging or pathology, Child-Pugh A-B liver function, ECOG performance status ≤ 2, and no severe comorbidities. The procedure involved selective hepatic artery catheterization to deliver pirarubicin-loaded hydrogel for embolization. Primary endpoints were procedure success rate, adverse events, tumor response (evaluated by changes in the maximum tumor diameter and mRECIST criteria for PR/SD/PD), and disease control rate (DCR). Follow-up was conducted for at least 4– 6 weeks for preliminary imaging assessment. Results: All 7 patients completed the procedure without failure or discontinuation. Tumor response was assessable in all patients: 2 achieved partial response (PR), 4 had stable disease (SD), and 1 had progression (PD). The objective response rate (ORR) was 28.6% (2/7), and the disease control rate (DCR) was 85.7% (6/7). Adverse events were mild, including fever, abdominal pain, and nausea/vomiting (grade 1– 2), with no severe toxicity (grade ≥ 3) or treatment interruption. Mild liver function fluctuations were observed in some patients, which recovered to baseline. Conclusion: Tepoxin combined with pirarubicin TACE is technically feasible and well-tolerated in HCC patients, showing early anti-tumor activity. Larger, well-designed studies are needed to confirm its efficacy and safety.

  • Open Access

    Correction: Trends and future projections of alcohol-attributable hepatitis B burden in women of childbearing age (1990–2040): a global analysis

    by Jiaxing Li, Qihui Hu, Jixing Wang, Zhenhao Huang, Hongli Cai, Chang Liu, Hao Li, Rui Tao

    A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval.• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used.The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.

  • PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury

    by Jiajie Leng, Zhenrui Cao, Letai Li, Dingheng Hu, Yuxiang Luo, Bin Tu, Xiaoying Cao, Rui Tao, Yingjiu Jiang, Hongtao Tie

    Objective This study investigates the dual regulatory role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) in macrophage polarization and its therapeutic potential for mitigating myocardial ischemia/reperfusion injury (MI/RI). Methods By integrating in vivo murine myocardial MI/RI models with macrophage-specific genetic manipulation and multi-omics analyses, including transcriptomics, proteomics, and energy metabolomics, we comprehensively investigated the cardio-protective effects, immune regulation, and potential mechanism of PGC1α. Mechanistic validations were performed using macrophage hypoxia/reoxygenation models combined with gain- and loss-of-function experiments to elucidate the molecular interactions within the PGC1α-mediated signaling network. Results PGC1α emerged as a potential regulator of macrophage polarization through coordinated metabolic and protein regulation in MI/RI. It suppresses TLR4/NF-κB-driven inflammation via two prominent parallel pathways: (1) Metabolic control through SUCLG1/succinyl-CoA synthetase-mediated succinate generation; (2) negatively regulates protein by TRAF5 mRNA expression inhibition. This dual-axis regulation effectively dampens M1 macrophage polarization and pro-inflammatory cytokine storms. Furthermore, macrophage-specific PGC1α activation demonstrated cardio-protective effects by preserving cardiac function and reducing cardiomyocyte apoptosis. Conclusion Our findings established PGC1α as a potential regulator of macrophage polarization in MI/RI, bridging mitochondrial energy metabolism and protein expression with immune responses. The PGC1α-SUCLG1/succinate axis and PGC1α-TRAF5 axis unveil therapeutic targets and potential mechanisms for modulating inflammation in MI/RI. Future studies should focus on translating these mechanisms into clinical interventions through pharmacological PGC1α activation.


  • Open Access

    Trends and future projections of alcohol-attributable hepatitis B burden in women of childbearing age (1990–2040): a global analysis

    by Jiaxing Li, Qihui Hu, Jixing Wang, Zhenhao Huang, Hongli Cai, Chang Liu, Hao Li, Rui Tao

    Introduction: Chronic hepatitis B virus (HBV) infection affects over 254 million people globally, with women of childbearing age (WCBA) facing dual risks of vertical transmission and alcohol-exacerbated disease progression. This study quantifies the alcohol-attributable burden of HBV among WCBA across 204 countries from 1990 to 2021 and projects trends to 2040. Methods: Data on deaths and Disability-Adjusted Life Years (DALYs) were extracted from the Global Burden of Diseases (GBD) Study 2021. Joinpoint regression and decomposition analyses were used to assess historical trends, while Bayesian Age-Period-Cohort (BAPC) analysis predicted future trends. Results: Between 1990 and 2021, global deaths showed a significant increase to 1,551.98 (95% UI: 700.34 to 2,707.01), accompanied by a rise in DALYs reaching 80,616.03 (95% UI: 37,268.53 to 139,146.25). This growth trajectory was primarily driven by population expansion. While age-standardized death and DALY rates exhibited a declining trend overall, epidemiological analysis revealed a transient rebound in DALYs between 1999 and 2005. Current projections using BAPC modeling suggest continued challenges, with deaths and DALYs anticipated to rise by 2040 under current intervention patterns. Conclusion: Despite declining age-standardized rates, population growth and alcohol exposure necessitate region-specific interventions. These findings underscore the urgent need for WHO alcohol control policies and HBV birth-dose vaccination in low-SDI regions, particularly sub-Saharan Africa and South Asia, to achieve 2030 elimination targets.


  • Open Access

    Global burden of metabolic-associated fatty liver disease among women of childbearing age: Trends from 1990 to 2021 and projections to 2040

    by Jiaxing Li, Qihui Hu, Jiajie Leng, Baoyong Zhou, Cong Chen, Yaoyue Hu, Bingdi Chao, Zhenhao Huang, Zhenrui Cao, Zhongling An, et al.

    Background: Metabolic-associated fatty liver disease (MAFLD) is a growing global health concern, particularly among women of childbearing age (WCBA). We aimed to analyze the global burden of MAFLD among WCBA from 1990 to 2021 and project trends to 2040. Methods: Data on incidence, prevalence, deaths, and disability-adjusted life years (DALYs) were extracted from the Global Burden of Disease Study 2021. Joinpoint regression and decomposition analysis were used to assess historical trends, and Bayesian Age-Period-Cohort (BAPC) modeling projected future burdens. Results: From 1990 to 2021, the age-standardized rate (ASR) of MAFLD incidence and prevalence among WCBA increased globally (EAPC = 0.76 and 0.71, respectively). China showed declining trends in deaths (EAPC = −2.63) and DALYs (EAPC = −2.62). By 2040, BAPC modeling predicts a continued rise in global incidence and prevalence, with regional disparities in mortality. Population growth was the primary driver of the global increase in MAFLD incidence, accounting for 63.38% of the rise. Conclusion: MAFLD imposes a significant burden on WCBA globally, with socioeconomic disparities driving regional variations. Targeted interventions addressing obesogenic environments and healthcare inequities are urgently needed.


  • Open Access

    Successful resection of a huge hepatocellular carcinoma during pregnancy: case report and review of the literature

    by Qihui Hu, Jiaxing Li, Jixing Wang, Cong Chen, Rui Tao

    Background: Hepatocellular carcinoma during pregnancy is rare and poses significant potential risks to both the pregnant individual and the fetus. Here, we report a case of hepatocellular carcinoma during pregnancy. The 28-week gestational is a critical point of fetal maturation. A literature review revealed no similar case with survival exceeding 2 years, following resection of a large hepatocellular carcinoma diagnosed in late-stage pregnancy. This article may contribute to future research aimed at extending the survival time of patients with hepatocellular carcinoma diagnosed in late pregnancy. Case presentation: A 33-year-old pregnant woman was diagnosed with hepatocellular carcinoma at 34 weeks of pregnancy. A cesarean section was performed at 34 weeks of pregnancy. Under general anesthesia, a right lobectomy of the liver was conducted after 15 days. The patient received continuous support from the clinical psychology team throughout the entire perioperative period. The postoperative recovery was smooth, and the patient was discharged without any significant complications. Approximately 2 years post-surgery, follow-up indicated that the patient remained alive and in good health. Conclusions: The physiological changes associated with pregnancy can promote rapid tumor growth, leading to poor prognoses. Expert decision-making should be guided by the growth and maturation status of the fetus in relation to hepatocellular carcinoma development. For patients in the late stage of pregnancy, timely termination of pregnancy and tumor resection surgery, along with obtaining assistance from the clinical psychology team during the perioperative period, followed by post-discharge treatment with a combination of Sintilimab and Lenvatinib, constitutes an effective strategy for prolonging patient survival.


  • A rapid and efficient microenvironment improving hyaluronic acid microneedle dressing for burn wound synergistic treatment

    by Lin Lei, Wei Li, Jiajia Wang, Qi Liu, Feng Zeng, Yunqiang Xiang, Xinyuan Fu, Rui Tao, Zhangyou Yang


  • Open Access

    Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma

    by Yanxi Yu, Yan You, Yuxin Duan, Meiqing Kang, Baoyong Zhou, Jian Yang, Kunli Yin, Wentao Ye, Ranning Xu, Hao Wang, et al.

    Background and Aims: The aims of the present study were to characterize the PANoptosis signature in intrahepatic cholangiocarcinoma (ICC) patients, construct a novel model to guide clinical diagnosis and treatment, and further explore the associated molecular mechanisms of drug resistance. Approach and Results: In total, 85 PANoptosis-related genes that possess both PANoptosis and multi-omics features were, respectively, screened from transcriptomic data from the OEP001105 public cohort and from transcriptomic and proteomic sequencing data from The First Affiliated Hospital of Chongqing Medical University. A novel framework integrating Cox regression analysis and 5 machine learning algorithms was developed to identify the 5 hub genes (POSTN, SFN, MYOF, HOGA1, and PECR). The subsequently constructed PANoptosis risk score demonstrates outstanding performance in predicting prognosis and clinical translation across multicenter cohorts with multi-omics profiling. Bulk and single-cell transcriptome profiling were used to investigate the tumor microenvironment, emphasizing the crucial role of macrophages in the tumor microenvironment of ICCs. Moreover, a positive spatial correlation of cancer-associated fibroblasts–derived POSTN expression with tumor-associated macrophages infiltration and PD-L1/PD-L2 expression in ICC patients was observed, suggesting that overexpression of POSTN may lead to resistance to immune checkpoint blockade therapy in ICC patients. Conclusions: The present study identified a precise prognostic and treatment strategy for ICC patients prone to PANoptosis, investigated the molecular mechanisms of PANoptosis in ICC cells, and highlighted the potential clinical relevance of the PANoptosis risk score in predicting prognosis and therapy response. These findings will help guide clinical treatment strategies for ICC.


  • Open Access

    Functional molecule-mediated assembled copper nanozymes for diabetic wound healing

    by Wenyan Huang, Ping Xu, Xiaoxue Fu, Jiaxin Yang, Weihong Jing, Yucen Cai, Yingjuan Zhou, Rui Tao, Zhangyou Yang

    Background: The complex hyperglycemic, hypoxic, and reactive oxygen species microenvironment of diabetic wound leads to vascular defects and bacterial growth and current treatment options are relatively limited by their poor efficacy. Results: Herein, a functional molecule-mediated copper ions co-assembled strategy was constructed for collaborative treatment of diabetic wounds. Firstly, a functional small molecule 2,5-dimercaptoterephthalic acid (DCA) which has symmetrical carboxyl and sulfhydryl structure, was selected for the first time to assisted co-assembly of copper ions to produce multifunctional nanozymes (Cu-DCA NZs). Secondly, the Cu-DCA NZs have excellent multicatalytic activity, and photothermal response under 808 nm irradiation. In vitro and in vivo experiments showed that it not only could efficiently inhibit bacterial growth though photothermal therapy, but also could catalyze the conversion of intracellular hydrogen peroxide to oxygen which relieves wound hypoxia and improving inflammatory accumulation. More importantly, the slow release of copper ions could accelerate cellular proliferation, migration and angiogenesis, synergistically promote the healing of diabetic wound furtherly. Conclusions: The above results indicate that this multifunctional nanozymes Cu-DCA NZs may be a potential nanotherapeutic strategy for diabetic wound healing.


  • HSP110 aggravates ischemia-reperfusion injury after liver transplantation by promoting NF-κB pathway

    by Qing-Zhi Hu, Zhen-Rui Cao, Wei-Xiong Zheng, Min-Jie Zhao, Jun-Hua Gong, Cong Chen, Zhong-Jun Wu, Rui Tao